66417-46-7

Basic information

• Product Name: 2-Propenoic acid, 3-(3-hydroxyphenyl)-, Methyl ester, (2E)-
• Synonyms: 2-Propenoic acid, 3-(3-hydroxyphenyl)-, Methyl ester, (2E)-;Methyl 3-(3-hydroxyphenyl)prop-2-enoate;Methyl trans-3-Hydroxycinnamate
• CAS NO: 66417-46-7
• Molecular Formula: C₁₀H₁₀O₃
• Molecular Weight: 178.1846
• EINECS: -0
• Mol File: 66417-46-7.mol
• Article Data: 32

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Propenoic acid, 3-(3-hydroxyphenyl)-, Methyl ester, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-(3-hydroxyphenyl)-, Methyl ester, (2E)-(66417-46-7)
• EPA Substance Registry System: 2-Propenoic acid, 3-(3-hydroxyphenyl)-, Methyl ester, (2E)-(66417-46-7)

Safety Data

• Hazardous Substances Data: 66417-46-7(Hazardous Substances Data)

Upstream product

• 5927-18-4 trimethyl phosphonoacetate 
• 100-83-4 meta-hydroxybenzaldehyde 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 
• 108-59-8 malonic acid dimethyl ester 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 
• 591-20-8 3-Bromophenol 
• 292638-85-8 acrylic acid methyl ester 
• 14755-02-3 3-hydroxycinnamic acid 
• 36653-82-4 1-Hexadecanol 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 86610-64-2 (E)-3-hydroxycinnamyl chloride 
• 86610-57-3 (E)-4-<(3-hydroxycinnamyl)thio>-1-β-D-ribofuranosyl-1H-pyrazolo<3,4-d>pyrimidine 
• 108781-69-7 2,3-Dibromo-3-(3-hydroxy-phenyl)-propionic acid methyl ester 
• 61389-68-2 methyl 3-(3-hydroxyphenyl)propionate 
• 122801-83-6 3-(3-phenoxyphenyl)propanal 
• 106797-69-7 3-(3-phenoxyphenyl)propan-1-ol 
• 115488-27-2 methyl 3-(3-phenoxyphenyl)propanoate 

Relevant articles and documents

Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines

We report the design, synthesis, and evaluation of potent and selective inhibitors of aldo-keto reductase 1C3 (AKR1C3), an important enzyme in the regulatory pathway controlling proliferation, differentiation, and apoptosis in myeloid cells. Combination treatment with the nontoxic AKR1C3 inhibitors and etoposide or daunorubicin in acute myeloid leukemia cell lines, elicits a potent adjuvant effect, potentiating the cytotoxicity of etoposide by up to 6.25-fold and the cytotoxicity of daunorubicin by >10-fold. The results validate AKR1C3 inhibition as a common adjuvant target across multiple AML subtypes. These compounds in coadministration with chemotherapeutics in clinical use enhance therapeutic index and may avail chemotherapy as a treatment option to the pediatric and geriatric population currently unable to tolerate the side effects of cancer drug regimens.

Antifungal activity of cinnamic acid and benzoic acid esters against Candida albicans strains

Candida albicans is an important opportunistic fungal pathogen capable of provoking infection in humans. In the present study, we evaluated the antifungal effect of 23 ester derivatives of the cinnamic and benzoic acids against 3 C. albicans strains (ATCC-76645, LM-106 and LM-23), as well as discuss their Structure–Activity Relationship (SAR). The antifungal assay results revealed that the screened compounds exhibited different levels of activity depending on structural variation. Among the ester analogues, methyl caffeate (5) and methyl 2-nitrocinnamate (10) were the analogues that presented the best antifungal effect against all C. albicans strains, presenting the same MIC values (MIC?=?128?μg/mL), followed by methyl biphenyl-2-carboxylate (21) (MIC?=?128, 128 and 256?μg/mL for C. albicans LM-106, LM-23, and ATCC-76645, respectively). Our results suggest that certain molecular characteristics are important for the antifungal action.

HIGHLY SELECTIVE AKR1C3 INHIBITORS AND METHODS OF USE THEREOF

The present invention includes methods and compositions that inhibit AKR1C3 enzymatic activity and consequently reduces androgen receptor (AR) transactivation, AR and prostate specific antigen (PSA) expression levels in, for example, prostate cancer, cast